Diethylcarbamazine

Diethylcarbamazine
Clinical data
Other names	DEC, N, N-diethyl-4-methyl-1-piperazine carboxamide
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	By mouth
ATC code	P02CB02 (WHO) QP52AH02 (WHO);
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name N,N-diethyl-4-methylpiperazine-1-carboxamide;
CAS Number	90-89-1 ;
PubChem CID	3052;
DrugBank	DB00711 ;
ChemSpider	2944 ;
UNII	V867Q8X3ZD;
KEGG	D07825 ;
ChEMBL	ChEMBL684 ;
CompTox Dashboard (EPA)	DTXSID1022928 ;
ECHA InfoCard	100.001.840
Chemical and physical data
Formula	C10H21N3O
Molar mass	199.298 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	47 to 49 °C (117 to 120 °F)
	SMILES C1CN(C)CCN1C(=O)N(CC)CC;
	InChI InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3 ; Key:RCKMWOKWVGPNJF-UHFFFAOYSA-N ;
	(verify)

Diethylcarbamazine is a medication used in the treatment of filariasis including lymphatic filariasis, tropical pulmonary eosinophilia, and loiasis. It may also be used for prevention of loiasis in those at high risk. While it has been used for onchocerciasis (river blindness), ivermectin is preferred. It is taken by mouth.

Common side effects include itching, facial swelling, headaches, and feeling tired. Other side effects include vision loss and dizziness. It is a recommended treatment in pregnancy and appears to be safe for the baby. The World Health Organization; however, recommends waiting until after pregnancy for treatment when feasible. It is made from 4-methyl-piperazine.

Diethylcarbamazine was discovered in 1947 by Yellapragada Subbarow. It is on the World Health Organization's List of Essential Medicines. It is not commercially available in the United States but can be acquired from the Centers for Disease Control and Prevention.